S&P 500 jumps as AMD rally leads tech higher
Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NASDAQ:NUVL), a $5.9 billion market cap biotech company, sold 4,000 shares of Class A Common Stock on September 29, 2025, at prices ranging from $81.39 to $84.92, totaling approximately $332,288. The stock currently trades at $82.58, and according to InvestingPro analysis, appears overvalued at current levels.
According to a Form 4 filing with the Securities and Exchange Commission, Noci also exercised options to acquire 4,000 shares of Class A Common Stock at $27.85 per share, for a total value of $111,400.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024. Following the transactions, Noci directly owns 48,034 shares of Nuvalent , Inc.
In other recent news, Nuvalent, Inc. has completed its New Drug Application submission to the U.S. Food and Drug Administration for zidesamtinib, targeting patients with advanced ROS1-positive non-small cell lung cancer who have been pre-treated with tyrosine kinase inhibitors. This marks a significant step for the company in advancing its lung cancer treatment portfolio. Additionally, Guggenheim has initiated coverage of Nuvalent with a Buy rating, citing the company’s potential in the lung cancer treatment market and setting a price target of $122.00. Piper Sandler also initiated coverage with an Overweight rating and a price target of $112.00, expressing optimism about Nuvalent’s potential for near-term value creation. Furthermore, Nuvalent is set to present pivotal data for zidesamtinib at the IASLC 2025 World Conference on Lung Cancer in Barcelona. The presentation will include results from the global ARROS-1 Phase 1/2 clinical trial for patients with advanced ROS1-positive non-small cell lung cancer. Lastly, the company has initiated a rolling NDA submission for zidesamtinib, with plans to complete it by the third quarter of 2025. The FDA has accepted this application for the Real-Time Oncology Review pilot program, facilitating earlier evaluation of its efficacy and safety results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.